N G Industries Ltd Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics Reflect Improved Price Attractiveness

The company’s price-to-earnings (P/E) ratio currently stands at 19.94, a figure that positions N G Industries as very attractively valued compared to its healthcare services peers. For context, competitors such as KMC Speciality and Suraksha Diagnostics trade at significantly higher P/E ratios of 44.74 and 48.97 respectively, while Gujarat Kidney and Gaudium IVF are priced at 91.15 and 36.66. This disparity underscores N G Industries’ relative undervaluation in the sector.

Similarly, the price-to-book value (P/BV) ratio of 1.15 further supports the stock’s valuation appeal. This is modest when juxtaposed with the sector’s more expensive names, indicating that the market is pricing N G Industries conservatively relative to its net asset base.

Enterprise value to EBITDA (EV/EBITDA) is another critical metric where N G Industries registers 20.48, which, while higher than some peers like GPT Healthcare (14.60) and Asarfi Hospital (11.01), remains below the valuations of several others such as Gujarat Kidney (52.55) and Lotus Eye Hospital (51.72). This suggests a balanced valuation stance, neither excessively cheap nor overpriced.

Financial Performance and Returns: A Mixed Picture

Despite the improved valuation, the company’s recent returns have been underwhelming relative to the Sensex benchmark. Year-to-date, N G Industries has declined by 21.54%, compared to the Sensex’s 12.82% drop. Over the past year, the stock has fallen 25.07%, significantly underperforming the Sensex’s 10.50% gain. Even over three years, the stock is down 14.40%, while the Sensex has appreciated by 9.91%.

However, the longer-term perspective offers a more positive narrative. Over five years, N G Industries has delivered a robust 117.70% return, substantially outpacing the Sensex’s 25.89% gain. The 10-year return of 57.86%, though trailing the Sensex’s 159.78%, still reflects meaningful capital appreciation for long-term investors.

These figures highlight a stock that has experienced volatility and recent underperformance but retains a history of strong gains, suggesting potential value for investors with a longer investment horizon.

Profitability and Efficiency Metrics Lag Sector Averages

Examining return metrics, N G Industries reports a return on capital employed (ROCE) of 3.55% and a return on equity (ROE) of 5.75%. These figures are modest and suggest limited efficiency in generating profits from capital and shareholder equity. In comparison, many healthcare services peers typically exhibit higher ROCE and ROE percentages, reflecting stronger operational performance.

Despite this, the company offers a dividend yield of 6.09%, which is attractive in the current low-yield environment and may appeal to income-focused investors seeking steady cash flows amid valuation uncertainties.

Market Capitalisation and Trading Activity

N G Industries is classified as a micro-cap stock, which often entails higher volatility and liquidity considerations. The stock price closed at ₹117.45 on 21 Sep 2026, a marginal increase of 0.17% from the previous close of ₹117.25. The day’s trading range was between ₹113.40 and ₹120.00, with a 52-week low of ₹110.20 and a high of ₹162.00, indicating a wide price band and potential for price recovery.

Peer Comparison Highlights Valuation Edge

When compared with a selection of healthcare services companies, N G Industries stands out for its valuation attractiveness. While peers such as KMC Speciality and Suraksha Diagnostics trade at P/E multiples exceeding 40, and some like Gujarat Kidney and Aashka Hospitals are classified as very expensive with P/E ratios above 60, N G Industries’ P/E below 20 is a compelling value proposition.

Moreover, the PEG ratio of 0.00 indicates the absence of expected earnings growth in the calculation, which may reflect market scepticism or lack of analyst coverage. This contrasts with peers like Suraksha Diagnostics, which has an anomalously high PEG of 26.41, suggesting market expectations of rapid growth or valuation anomalies.

Mojo Score and Rating Update

The company’s MarketsMOJO score currently stands at 31.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 18 Sep 2026. This upgrade signals a slight improvement in the company’s overall outlook, although the rating remains cautious. The micro-cap status and modest profitability metrics likely weigh on the sentiment, despite the improved valuation.

Investment Implications and Outlook

The shift in valuation grading from attractive to very attractive for N G Industries Ltd suggests that the stock is currently priced to offer better value relative to its historical multiples and sector peers. Investors seeking exposure to healthcare services at a reasonable valuation may find this stock worthy of consideration, particularly given its dividend yield of over 6%.

However, the company’s modest profitability ratios and recent underperformance relative to the Sensex highlight risks that should not be overlooked. The micro-cap classification adds an element of volatility and liquidity risk, which may not suit all investors.

Long-term investors who can tolerate short-term fluctuations might view the current valuation as an opportunity to accumulate shares at a discount, especially given the stock’s strong five-year return history. Conversely, those prioritising growth and operational efficiency may prefer to explore peers with higher ROCE and ROE metrics despite their richer valuations.

Overall, the valuation reset provides a fresh lens through which to analyse N G Industries, balancing its price appeal against fundamental challenges and market positioning.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today